Wells Fargo
FMTX

Wells Fargo’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Wells Fargo’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-352
Closed -$7K – 7930
2022
Q3 		$7K Sell
352
-370
-51% -$4.88K ﹤0.01% 5836
2022
Q2 		$5K Sell
722
-2,759
-79% -$19.4K ﹤0.01% 6052
2022
Q1 		$33K Sell
3,481
-12,895
-79% -$137K ﹤0.01% 5836
2021
Q4 		$232K Buy
16,376
+8,842
+117% +$153K ﹤0.01% 5186
2021
Q3 		$175K Sell
7,534
-40,567
-84% -$959K ﹤0.01% 5160
2021
Q2 		$1.2M Buy
48,101
+46,691
+3,311% +$1.25M ﹤0.01% 4085
2021
Q1 		$40K Sell
1,410
-23,149
-94% -$835K ﹤0.01% 5921
2020
Q4 		$857K Buy
24,559
+12,351
+101% +$538K ﹤0.01% 4146
2020
Q3 		$609K Buy
+12,208
New +$493K ﹤0.01% 4209

Wells Fargo's FMTX Position: Q4 2022 in Review

Wells Fargo sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 352 shares — an estimated $7K sold.

Wells Fargo first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $1.2M in Q2 2021. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • Wells Fargo reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Wells Fargo sold 352 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $7K.
  • Wells Fargo first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Wells Fargo's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $1.2M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Wells Fargo's 13F filing for Q4 2022, filed 13 Feb 2023.